Work

507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.586

Authors: P.A. Jänne, B-C. Wang, B.C. Cho, J. Zhao, J. Li, M.J. Hochmair, S. Peters, B. Besse, T. Kato, Y-L. Wu, D. Nguyen, J. Lin, J. Lin, F. Vranceanu, M. Lin, R.J. Fram, T.S.K. Mok

Institutions: Dana-Farber Cancer Institute, Guangdong Provincial People's Hospital, Yonsei University, Yonsei Cancer Hospital, Peking University Cancer Hospital, Sichuan Cancer Hospital, Centre Hospitalier Universitaire Vaudois, Institut Gustave Roussy, Kanagawa Cancer Center, Guangdong Academy of Medical Sciences, South China University of Technology, City Of Hope National Medical Center, Takeda (United States), Chinese University of Hong Kong, Prince of Wales Hospital

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4389280218

FWCI: 5.782

Cites:

Cited by: 36

Related to: 10